La vendita allo scoperto per Alector dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Alector. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Alector (NASDAQ:ALEC) Azioni, Report sulle vendite allo scoperto

Alector

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector Inc

WIIM

GAME

GameSquare shares are trading lower after the company reported worse-than-expected Q3 revenue results.

REKR

Rekor Systems shares are trading lower after the company reported worse-than-expected Q3 financial results.

Fundamental Global shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

News

Events

Trading Ideas

OKLO

Live On CNBC, Oklo Co-Founder And CEO Jacob DeWitte Discusses Q3 Results, Nuclear Power & Trump

Arm Holdings shares are trading lower after NVIDIA's 13F showed it had decreased its stake in the company by 13%.

<p>RBC Capital  analyst Nelson Ng   reiterates Northland Power (CSE2: NPI) with a Outperform and maintains C$28 price target.</p>


Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Northland Power, Maintains C$28 Price Target

GE Vernova shares are trading higher after Morgan Stanley raised the price target from $301 to $367 on the stock

<p>President-elect <strong>Donald Trump</strong>'s proposed Department of Government Efficiency (DOGE), led by <strong>Elon Musk</strong> and <strong>Vivek</strong> <strong>Ramaswamy</strong>, is raising questions about the future of U.S. defense contractors <a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently">and government IT firms. </a></p>
<p>Could the defense budget flatten—or even fall? And who stands to gain in this new sector shake up?</p>
<h3 class="wp-block-heading">DOGE Puts Defense Budget Under Pressure</h3>
<p>Trump's plan to restructure federal agencies and reduce wasteful spending through DOGE is a bold move, and its potential ripple effects are hard to ignore—especially for defense and government IT companies. </p>
<p>With the Department of Defense (DoD) being one of the largest slices of federal spending, investors are understandably focused on what's next for defense stocks in a DOGE-driven world.</p>
<p>On one hand, Trump's campaign has consistently expressed support for strengthening the U.S. military. </p>
<p>On the other, it's hard to make sweeping government cuts without touching the $877 billion defense budget, which accounts for 13% of federal spending as of 2023.</p>
<p><strong>Read Also:</strong> <strong><a href="https://www.benzinga.com/24/11/41965420/department-of-government-efficiency-led-by-elon-musk-and-vivek-ramaswamy-opens-x-account-with-username-doge">Elon Musk, Vivek Ramaswamy-Led Department Of Government Efficiency Opens Account On X</a></strong></p>
<h3 class="wp-block-heading">Defense Spending At All-Time Highs Spells Risks</h3>
<p>Historically, defense spending runs in decades-long cycles. Investment in the sector experiences periods of growth followed by downturns, and we may be nearing the peak of the current cycle, according to Goldman Sachs analyst Noah Poponak.</p>
<p> &#8220;The defense budget is at an all-time high, which creates difficult comparisons and challenging base effects,&#8221; the analyst said in a note published Friday. </p>
<h3 class="wp-block-heading"><strong>Key Risks For Defense Stocks</strong></h3>
<ol>
<li><strong>Peak Spending</strong>: The defense budget is hovering at historical highs, making future growth difficult.</li>
<li><strong>Geopolitical Shifts</strong>: If major conflicts ease, defense spending could decline.</li>
<li><strong>Government Debt</strong>: U.S. debt-to-GDP ratios are near record levels, increasing pressure to curb federal spending.</li>
</ol>
<p>Margins in the defense industry are already under pressure due to Pentagon efforts to shift risks onto contractors. Fixed pricing on long-term contracts, for example, has eroded unit economics. </p>
<p>At the same time, defense stocks – as tracked by the <strong>SPDR S&amp;P Aerospace &amp; Defense ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>) – are trading at valuations above historical averages, leaving them vulnerable to a "de-rating" if the budget flattens or falls.</p>
<p>&#8220;It is difficult to embark on any large government spending reduction effort without touching defense, and there are potentially enough inefficiencies within the defense budget to reduce its total level without necessarily reducing military readiness or capability,&#8221; Poponak said. </p>
<p>The investment bank maintains a cautious stance on the defense sector, issuing Sell ratings for <strong>Lockheed Martin Corp. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), <strong>Northrop Grumman Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), <strong>L3Harris Technologies Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), and <strong>Huntington Ingalls Industries Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>).</p>
<h3 class="wp-block-heading">Government IT: Winners In The Efficiency Game?</h3>
<p>While defense hardware could take a hit, government IT firms might find themselves potentially on the winning side of DOGE. </p>
<p>The sector has been outperforming traditional defense industries in revenue growth, driven by a market share shift toward advanced technologies like artificial intelligence, data analytics, and cybersecurity.</p>
<h3 class="wp-block-heading"><strong>Why IT Could Shine</strong>:</h3>
<ul>
<li><strong>Tech-Driven Efficiency</strong>: DOGE's focus on cutting waste could emphasize the adoption of technologies that streamline government operations.</li>
<li><strong>Advanced Capabilities</strong>: Firms offering cutting-edge solutions may be seen as key enablers of government efficiency.</li>
<li><strong>Resilient Demand</strong>: Even with DoD cuts, IT spending for Operations &amp; Maintenance and national security could remain strong.</li>
</ul>
<p>Goldman Sachs believes that companies like <strong>Booz Allen Hamilton Holding Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) and <strong>Leidos Holdings Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) are well-positioned to benefit.</p>
<p>On the flip side,<strong> SAIC Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>) faces challenges due to slower growth and tougher competition, earning it a Sell rating from Goldman Sachs.</p>
<p>The bottom line is that Investors should prepare for a sector shakeup, as the creation of DOGE could mark a significant shift in federal spending priorities.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/42006982/activist-investor-nelson-peltz-says-he-was-a-matchmaker-for-elon-musk-with-donald-trump">Activist Investor Nelson Peltz Says He Was &#8216;A Matchmaker&#8217; For Elon Musk With Donald Trump</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Equities

Government

Large Cap

Mid Cap

Regulations

Sector ETFs

Contracts

Politics

Economics

Tech

ETFs

LDOS

SAIC

Trump's DOGE Plan: Goldman Sachs Says Defense Stocks Face Risks, IT Firms Could Win

<p>Americans are <a href="https://www.benzinga.com/markets/equities/24/05/38901540/gen-z-is-charging-too-much-and-not-paying-bills-what-the-latest-credit-card-delinquency-data-say">racking up debt</a> and having a difficult time paying it off. </p>
<p>The 30 or more day delinquency rate for <strong>Discover Financial Services </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) ticked up slightly in October from 3.84% to 3.87%. This is slightly lower than the Riverwoods, Illinois-based company&#8217;s yearly high of 4.02% in January.</p>
<p>Rates are slightly higher at <strong>Capital One Financial Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), ending the month at 4.61%, slightly higher than September&#8217;s 4.53%.</p>
<p><strong>American Express Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is known for its wealthier consumer base. The New York, New York-based company has not yet released delinquency data for October, but its 30+ day rate stood at 1.4% in September.</p>
<p>Higher delinquency rates can lead to increased provisions for credit losses and tighter lending standards.</p>
<p><strong>Delinquency on the Rise:</strong> The Federal Bank of New York released its quarterly debt <a href="https://www.newyorkfed.org/medialibrary/interactives/householdcredit/data/pdf/HHDC_2024Q3">report</a> on Wednesday.</p>
<p>The report found that total household debt increased by $147 billion to $17.94 trillion in 2024&#8217;s third quarter. Credit card balances increased by $24 billion to $1.17 trillion, 8.1% higher than it was a year ago.</p>
<p>Credit card delinquency rates improved slightly overall, with 8.8% of balances transitioning to delinquency compared to 9.1% last quarter.</p>
<p>The percentage of credit card debt 90 or more days delinquent has risen faster than any other debt type in 2024.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Econ #s

Personal Finance

Credit Card Delinquencies Tick Up At Discover, Capital One: Total Household Debt Hovers Just Below $18 Trillion

<p>RBC Capital  analyst Greg Pardy   maintains Strathcona Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SCR#TSX">SCR</a>) with a Sector Perform and raises the price target from C$34 to C$36.</p>


TSX:SCR

RBC Capital Maintains Sector Perform on Strathcona Resources, Raises Price Target to C$36

Disney shares are trading higher after the company announced it projects strong earnings growth especially in its ad supported streaming plans.

<p>Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Biogen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 26% leaning bullish and 66% bearish. Among these notable options, 2 are puts, totaling $80,703, and 13 are calls, amounting to $4,937,387.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $230.0 for Biogen, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Biogen options trades today is 1866.8 with a total volume of 4,855.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $110.0 to $230.0 over the last 30 days.</p>
<h3>Biogen 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688345_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$1.5M</td>
<td>8.7K</td>
<td align="right">751</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.6</td>
<td>$65.5</td>
<td>$65.5</td>
<td>$110.00</td>
<td>$1.0M</td>
<td>8.7K</td>
<td align="right">896</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.6</td>
<td>$62.5</td>
<td>$62.5</td>
<td>$110.00</td>
<td>$625.0K</td>
<td>8.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.5</td>
<td>$62.6</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$375.6K</td>
<td>8.7K</td>
<td align="right">231</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$319.2K</td>
<td>8.7K</td>
<td align="right">108</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>After a thorough review of the options trading surrounding Biogen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Biogen</h3>
<ul>
<li>Currently trading with a volume of 610,232, the BIIB's price is down by -2.38%, now at $160.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What The Experts Say On Biogen</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $219.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180.<br />
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $204.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $270.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Biogen, maintaining a target price of $255.<br />
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $190.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

BIIB

Biogen Unusual Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNPS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Synopsys. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 25% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $88,885, and 5 are calls, amounting to $268,163.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $670.0 for Synopsys during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Synopsys stands at 140.67, with a total volume reaching 322.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Synopsys, situated within the strike price corridor from $520.0 to $670.0, throughout the last 30 days.</p>
<h3>Synopsys Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688340_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$54.7</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$76.3K</td>
<td align="right">13</td>
<td align="right">18</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$41.8</td>
<td>$36.7</td>
<td>$38.0</td>
<td>$520.00</td>
<td>$61.7K</td>
<td align="right">43</td>
<td align="right">0</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$620.00</td>
<td>$46.2K</td>
<td align="right">367</td>
<td align="right">154</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$29.3</td>
<td>$28.4</td>
<td>$28.0</td>
<td>$540.00</td>
<td>$45.7K</td>
<td align="right">105</td>
<td align="right">5</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$38.1K</td>
<td align="right">13</td>
<td align="right">33</td>
</tr>
</tbody>
</table>
</p>
<h3>About Synopsys</h3>
<p>Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.</p>
<p>Having examined the options trading patterns of Synopsys, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Synopsys's Current Market Status</h3>
<ul>
<li>With a trading volume of 217,362, the price of SNPS is down by -3.59%, reaching $528.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>Expert Opinions on Synopsys</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $658.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Loop Capital downgraded its action to Buy with a price target of $675.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Synopsys with a target price of $670.<br />
&#x2A; In a cautious move, an analyst from Mizuho downgraded its rating to Outperform, setting a price target of $650.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $640. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Synopsys options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SNPS

Synopsys Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on NIO. Our analysis of options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $498,343, and 4 were calls, valued at $260,650.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $17.5 for NIO, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NIO's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NIO's substantial trades, within a strike price spectrum from $3.0 to $17.5 over the preceding 30 days.</p>
<h3>NIO Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688335_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.97</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$5.00</td>
<td>$219.3K</td>
<td>60.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.98</td>
<td>$0.96</td>
<td>$0.97</td>
<td>$5.00</td>
<td>$153.3K</td>
<td>60.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.41</td>
<td>$1.35</td>
<td>$1.4</td>
<td>$5.00</td>
<td>$140.0K</td>
<td>51.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.05</td>
<td>$13.0</td>
<td>$13.05</td>
<td>$17.50</td>
<td>$62.6K</td>
<td>75</td>
<td>48</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.43</td>
<td>$1.41</td>
<td>$1.43</td>
<td>$5.00</td>
<td>$42.1K</td>
<td>51.2K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About NIO</h3>
<p>Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.</p>
<p>After a thorough review of the options trading surrounding NIO, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of NIO</h3>
<ul>
<li>Trading volume stands at 19,370,337, with NIO's price down by -0.93%, positioned at $4.39.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>What Analysts Are Saying About NIO</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $6.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Macquarie upgrades its rating to Outperform with a revised price target of $6. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for NIO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


This Is What Whales Are Betting On NIO

ELAN

Elanco Acquires Speke Manufacturing Facility For $25M, Securing Critical Supply Chain For Farm Animal Products Generating $160M-$180M Annually; Expected To Impact 2025 Adjusted EBITDA By $25M-$35M

<p>RBC Capital  analyst Logan Reich   reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and maintains $70 price target.</p>


RBC Capital Reiterates Outperform on Chipotle Mexican Grill, Maintains $70 Price Target

COIN

Coinbase shares are trading higher after the company recently announced it acquired on-chain payments platform Utopia Labs.

<p>Piper Sandler  analyst Brian Mullan   maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Neutral and raises the price target from $100 to $142.</p>


CAVA

Piper Sandler Maintains Neutral on Cava Group, Raises Price Target to $142

<p>Piper Sandler  analyst Alexander Goldfarb   maintains Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) with a Neutral and lowers the price target from $5 to $4.5.</p>


Piper Sandler Maintains Neutral on Hudson Pacific Properties, Lowers Price Target to $4.5

<p>RBC Capital  analyst Logan Reich   reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Outperform and maintains $115 price target.</p>


SBUX

RBC Capital Reiterates Outperform on Starbucks, Maintains $115 Price Target

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

In a report released today, Carter Gould from Barclays assigned a Buy rating to Alector (ALEC – Research Report), with a price target of $12.00. Th...

Alector (ALEC) Receives a Buy from Barclays

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Alector (ALEC – Research Report) yesterday. The company's shares closed yest...

Mizuho Securities Reaffirms Their Buy Rating on Alector (ALEC)

TD Cowen analyst Yaron Werber has maintained their bullish stance on ALEC stock, giving a Buy rating on November 4. Yaron Werber has given his Buy ...

Alector's Promising Phase 2 Study and Strong Financial Outlook Justify Buy Rating

Alector GAAP EPS of -$0.43 beats by $0.14, revenue of $15.34M misses by $0.55M

In a report released today, Carter Gould from Barclays maintained a Buy rating on Alector (ALEC – Research Report), with a price target of $12.00. ...

Barclays Reaffirms Their Buy Rating on Alector (ALEC)

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), retaining the price target of $35.00. Andrew Fe...

Promising Developments in Alector's Alzheimer's Treatments Drive Buy Rating

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alector (ALEC – Research Report) today and set a price target of $15.00. The compan...

Stifel Nicolaus Sticks to Its Buy Rating for Alector (ALEC)

Analyst Graig Suvannavejh of Mizuho Securities maintained a Buy rating on Alector (ALEC – Research Report), with a price target of $9.00. Graig Suv...

Optimistic Outlook for Alector Amid Anticipated Alzheimer's Treatment Breakthrough

Alector ( ($ALEC) ) has provided an update. Alector, a clinical-stage biotechnology company, has secured a $50 million credit facility from Hercule...

Alector Secures Funding to Advance Clinical Trials

ABBV

ALEC

AMRX

COYA

SAVA

SAVAW

Press Releases

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Health Care

Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Host Mid-Year Earnings Conference Call

Earnings

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Participate in Upcoming Healthcare Conferences

General

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Financing

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Comments

Alector

Vendite allo scoperto

Alector (NASDAQ:ALEC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO